Trial · NCT06314698
Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
NCT06314698, Phase 3, Not yet recruiting, RenJi Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease. Trials, record NCT06314698. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06314698
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease
- NCT number
- NCT06314698
- Status
- Not yet recruiting
- Phases
- Phase 3
- Enrollment
- 478 participants, estimated
- Lead sponsor
- RenJi Hospital
- Conditions
- Multiple Myeloma, Bone Diseases
- Interventions
- Narlumosbart, Denosumab
- First posted
- 2024-03-18
- Last updated
- 2024-03-18
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent change from baseline in urinary N-terminal telopeptide of type 1 collagen corrected for urinary creatinine (uNTx/uCr) at week 13 | From baseline to week 13 | Compare narlumosbart and denosumab for percentage change in bone turnover marker (BTM) - urinary N-terminal telopeptide of type 1 collagen (uNTx) corrected for urinary creatinine (uCr) (uNTx/uCr from baseline to week 13) |
| Secondary | The proportion of subjects with a change in uNTx/uCr greater than 65% from baseline to week 13 | From baseline to week 13 | Compare narlumosbart and denosumab for the proportion of subjects with a change in uNTx/uCr greater than 65% from baseline to week 13 (uNTx/uCr from baseline to week 13 \>65%) |
| Secondary | Time to first on-study skeletal related event | From baseline to 90 days after the last dose, up to approximately 30 months | A skeletal-related event (SRE) is defined as one of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE |
| Secondary | Percentage of participants with an on-study SRE at different time points | Months 3, 6, 12, 18 and 24 | A skeletal-related event (SRE) is defined as one of the following: pathologic fracture, radiation therapy to bone, surgery to bone, or spinal cord compression. Percentage of participants with an on-study SRE at 3, 6, 12, 18 and 24 months |
| Secondary | Time to first and subsequent on-study SRE | From baseline to 90 days after the last dose, up to approximately 30 months | Time to first on-study SRE is defined as the time interval (in days) from the randomization date to the date of first occurrence of on-study SRE. Time to a subsequent SRE is defined, similarly to the time to first on-study SRE, as the time interval from the randomization date to the date of a subsequent occurrence of on-study SRE, which had to be at least 21 days after the previous SRE. |
| Secondary | Percent changes of serum bone alkaline phosphatase (BALP) and serum C-terminal telopeptide of type 1 collagen (sCTX-I) | From baseline to week 13 | Compare the changes of BALP and sCTX-I from baseline to weeks 13 |
| Secondary | Overall Survival | From baseline to 90 days after the last dose, up to approximately 30 months | Overall survival was defined as the time interval (in days) from the randomization date to the date of death. |
| Secondary | Incidence and type of adverse events (AEs) | From the first dose finished to 28 days after the last dose | To identify the incidence and the type of AEs, including abnormalities in clinical, laboratory assessments, ECGs, echocardiography, vital sign assessments, and physical exams. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38112898 | BACKGROUND |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06314698
GET https://conductscience.org/api/trials/v1/NCT06314698/registered